Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer
- 15 September 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (18), 5288-5301
- https://doi.org/10.1158/0008-5472.can-16-0194
Abstract
New combination immunotherapies are displaying both efficacy and immune-related adverse events (irAE) in humans. However, grade 3/4 irAEs occur in a high proportion, which can lead to discontinuation of treatment and can result in fatalities if not promptly treated. Prolonged T regulatory cell (Treg) depletion in tumor-bearing Foxp3-DTR mice using diphtheria toxin (DT) mirrored the spectrum of antitumor responses and severity of irAEs that can occur in ipilimumab/nivolumab-treated patients. In contrast, transient Treg depletion or anti-CTLA-4/PD-1 therapy had equivalent effects in mice, lowering the immune tolerance threshold and allowing irAEs to be more easily induced following treatment with additional immunomodulatory antibodies. Transient Treg depletion of DT in combination with anti-PD-1 or anti-TIM-3 monoclonal antibodies had a high therapeutic window compared with DT plus anti-CD137. In contrast, DT plus anti-CD137–treated mice developed severe irAEs similar to grade 3/4 clinical symptoms. These irAEs appeared because of an infiltration of activated proliferating effector T cells in the tissues producing IFNγ and TNF; however, TNF blockade decreased irAEs severity without impacting on tumor growth. Cancer Res; 76(18); 5288–301. ©2016 AACR.Keywords
Other Versions
This publication has 52 references indexed in Scilit:
- Cocktails for cancer with a measure of immunotherapyNature, 2016
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals Of Oncology, 2015
- Boosting Cancer Immunotherapy with Anti-CD137 Antibody TherapyClinical Cancer Research, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapiesClinical & Translational Immunology, 2014
- The delicate balance of melanoma immunotherapyClinical & Translational Immunology, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Eradication of established tumors in mice by a combination antibody-based therapyNature Medicine, 2006